Expression and localization of the immunophilin FKBP51 in colorectal carcinomas and primary metastases, and alterations following oxaliplatin-based chemotherapy

Rotoli,Deborah; Morales,Manuel; Maeso,María  del Carmen; García,María  del Pino; Morales,Araceli; Ávila,Julio; Martín‑Vasallo,Pablo

doi:10.3892/ol.2016.4772

Expression and localization of the immunophilin FKBP51 in colorectal carcinomas and primary metastases, and alterations following oxaliplatin-based chemotherapy

Authors:
- Deborah Rotoli
- Manuel Morales
- María del Carmen Maeso
- María del Pino García
- Araceli Morales
- Julio Ávila
- Pablo Martín‑Vasallo
View Affiliations

Affiliations: Developmental Biology Laboratory, UD- Biochemistry and Molecular Biology and Centre for Biomedical Research of the Canary Islands, La Laguna University, La Laguna, 38206 Tenerife, Spain, Service of Medical Oncology, University Hospital Nuestra Señora de Candelaria, 38010 Santa Cruz de Tenerife, Spain, Service of Pathology, University Hospital Nuestra Señora de Candelaria, 38010 Santa Cruz de Tenerife, Spain, Laboratory of Biopathology, Hospiten® Hospitals, 38010 Tenerife, Spain, Department of Physiology, Institute of Biomedical Technologies, School of Medicine and Centre for Biomedical Research of The Canary Islands, University of La Laguna, La Laguna, 38071 Santa Cruz de Tenerife, Spain
Published online on: June 23, 2016 https://doi.org/10.3892/ol.2016.4772
Pages: 1315-1322
Copyright: © Rotoli et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The immunophilin FK506-binding protein 5 (FKBP51) is a scaffold protein that serves a pivotal role in the regulation of multiple signaling pathways, integrating external and internal stimuli into distinct signal outputs. In a previous study, we identified several genes that are significantly up‑ or downregulated in the peripheral white cells (PWCs) of colorectal adenocarcinoma (CRC) patients undergoing oxaliplatin-based chemotherapy. In our screening, FKBP51 gene expression was downregulated following chemotherapy. In order to determine whether this alteration in gene expression observed in PWCs may be detected at the protein level in tumors and metastases following the administration of adjuvant chemotherapy, an immunohistochemical analysis of FKBP51 in CRC and primary metastasis tissues was performed. The present study confirmed the downregulation of FKBP51 gene expression elicited by chemotherapy with folinic acid (leucovorin), fluorouracil and oxaliplatin in metastasized liver tissue that had been resected after the oxaliplatin-based chemotherapy, compared with tissue section samples of CRC from patients (prior to antineoplastic treatment). Furthermore, the results indicated that, in CRC tissue sections, the expression of FKBP51 protein is associated with an immature phenotype of stromal fibroblasts and with the epithelial-to-mesenchymal transition (EMT) phenotype, suggesting a role for this protein in the EMT process in CRC. Finally, the observation that only certain cells of the stroma express FKBP51 protein suggests a potential role for this immunophilin as a stroma cell subtype marker.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Xu R, Zhou B, Fung PC and Li X: Recent advances in the treatment of colon cancer. Histol Histopathol. 21:867–872. 2006.PubMed/NCBI
3	André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 350:2343–2351. 2004. View Article : Google Scholar : PubMed/NCBI
4	Raymond E, Chaney SG, Taamma A and Cvitkovic E: Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol. 9:1053–1071. 1998. View Article : Google Scholar : PubMed/NCBI
5	Morales M, Ávila J, González-Fernández R, Boronat L, Soriano ML and Martín-Vasallo P: Differential transcriptome profile of peripheral white cells to identify biomarkers involved in oxaliplatin induced neuropathy. J Pers Med. 4:282–296. 2014. View Article : Google Scholar : PubMed/NCBI
6	Erlejman AG, De Leo SA, Mazaira GI, Molinari AM, Camisay MF, Fontana V, Cox MB, Piwien-Pilipuk G and Galigniana MD: NF-kB transcriptional activity is modulated by FK506-binding proteins FKBP51 and FKBP52: A role for peptidyl-prolyl isomerase activity. J Biol Chem. 289:26263–26276. 2014. View Article : Google Scholar : PubMed/NCBI
7	Gallo LI, Lagadari M, Piwien-Pilipuk G and Galigniana MD: The 90-kDa heat-shock protein (Hsp90)-binding immunophilin FKBP51 is a mitochondrial protein that translocates to the nucleus to protect cells against oxidative stress. J Biol Chem. 286:30152–30160. 2011. View Article : Google Scholar : PubMed/NCBI
8	Li L, Lou Z and Wang L: The role of FKBP5 in cancer aetiology and chemoresistance. Br J Cancer. 104:19–23. 2011. View Article : Google Scholar : PubMed/NCBI
9	Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z and Wang L: FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell. 16:259–266. 2009. View Article : Google Scholar : PubMed/NCBI
10	Romano S, D'Angelillo A, Pacelli R, Staibano S, De Luna E, Bisogni R, Eskelinen EL, Mascolo M, Cali G, Arra C and Romano MF: Role of FK506-binding protein 51 in the control of apoptosis of irradiated melanoma cells. Cell Death Differ. 17:145–157. 2010. View Article : Google Scholar : PubMed/NCBI
11	Romano S, Staibano S, Greco A, Brunetti A, Nappo G, Ilardi G, Martinelli R, Sorrentino A, Di Pace A, Mascolo M, et al: FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential. Cell Death Dis. 4:e5782013. View Article : Google Scholar : PubMed/NCBI
12	Romano S, D'Angelillo A, D'Arrigo P, Staibano S, Greco A, Brunetti A, Scalvenzi M, Bisogni R, Scala I and Romano MF: FKBP51 increases the tumour-promoter potential of TGF-beta. Clin Transl Med. 3:12014. View Article : Google Scholar : PubMed/NCBI
13	Storer CL, Dickey CA, Galigniana MD, Rein T and Cox MB: FKBP51 and FKBP52 in signaling and disease. Trends Endocrinol Metab. 22:481–490. 2011. View Article : Google Scholar : PubMed/NCBI
14	Hubler TR, Denny WB, Valentine DL, Cheung-Flynn J, Smith DF and Scammell JG: The FK506-binding immunophilin FKBP51 is transcriptionally regulated by progestin and attenuates progestin responsiveness. Endocrinology. 144:2380–2387. 2003. View Article : Google Scholar : PubMed/NCBI
15	Jinwal UK, Koren J III, Borysov SI, Schmid AB, Abisambra JF, Blair LJ, Johnson AG, Jones JR, Shults CL, O'Leary JC III, et al: The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules. J Neurosci. 30:591–599. 2010. View Article : Google Scholar : PubMed/NCBI
16	Chambraud B, Sardin E, Giustiniani J, Dounane O, Schumacher M, Goedert M and Baulieu EE: A role for FKBP52 in Tau protein function. Proc Natl Acad Sci USA. 107:2658–2663. 2010. View Article : Google Scholar : PubMed/NCBI
17	Li L, Fridley B, Kalari K, Jenkins G, Batzler A, Safgren S, Hildebrandt M, Ames M, Schaid D and Wang L: Gemcitabine and cytosine arabinoside cytotoxicity: Association with lymphoblastoid cell expression. Cancer Res. 68:7050–7058. 2008. View Article : Google Scholar : PubMed/NCBI
18	Varghese F, Bukhari AB, Malhotra R and De A: IHC Profiler: An open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS One. 9:e968012014. View Article : Google Scholar : PubMed/NCBI
19	Bleau AM, Agliano A, Larzabal L, de Aberasturi AL and Calvo A: Metastatic dormancy: A complex network between cancer stem cells and their microenvironment. Histol Histopathol. 29:1499–1510. 2014.PubMed/NCBI
20	Ha SY, Yeo SY, Xuan Y and Kim SH: The prognostic significance of cancer-associated fibroblasts in esophageal squamous cell carcinoma. PLoS One. 9:e999552014. View Article : Google Scholar : PubMed/NCBI
21	Nalbantoglu IL, Tan BR Jr, Linehan DC, Gao F and Brunt EM: Histological features and severity of oxaliplatin-induced liver injury and clinical associations. J Dig Dis. 15:553–560. 2014. View Article : Google Scholar : PubMed/NCBI
22	Davies TH, Ning YM and Sánchez ER: A new first step in activation of steroid receptors: Hormone-induced switching of FKBP51 and FKBP52 immunophilins. J Biol Chem. 277:4597–4600. 2002. View Article : Google Scholar : PubMed/NCBI
23	Galigniana MD, Radanyi C, Renoir JM, Housley PR and Pratt WB: Evidence that the peptidylprolyl isomerase domain of the hsp90-binding immunophilin FKBP52 is involved in both dynein interaction and glucocorticoid receptor movement to the nucleus. J Biol Chem. 276:14884–14889. 2001. View Article : Google Scholar : PubMed/NCBI
24	Wochnik GM, Rüegg J, Abel GA, Schmidt U, Holsboer F and Rein T: FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J Biol Chem. 280:4609–4616. 2005. View Article : Google Scholar : PubMed/NCBI
25	Sidler D, Renzulli P, Schnoz C, Berger B, Schneider-Jakob S, Flück C, Inderbitzin D, Corazza N, Candinas D and Brunner T: Colon cancer cells produce immunoregulatory glucocorticoids. Oncogene. 30:2411–2419. 2011. View Article : Google Scholar : PubMed/NCBI
26	Baughman G, Wiederrecht GJ, Chang F, Martin MM and Bourgeois S: Tissue distribution and abundance of human FKBP51, and FK506-binding protein that can mediate calcineurin inhibition. Biochem Biophys Res Commun. 232:437–443. 1997. View Article : Google Scholar : PubMed/NCBI
27	Mukaide H, Adachi Y, Taketani S, Iwasaki M, Koike-Kiriyama N, Shigematsu A, Shi M, Yanai S, Yoshioka K, Kamiyama Y and Ikehara S: FKBP51 expressed by both normal epithelial cells and adenocarcinoma of colon suppresses proliferation of colorectal adenocarcinoma. Cancer Invest. 26:385–390. 2008. View Article : Google Scholar : PubMed/NCBI
28	Jiang W, Cazacu S, Xiang C, Zenklusen JC, Fine HA, Berens M, Armstrong B, Brodie C and Mikkelsen T: FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway. Neoplasia. 10:235–243. 2008. View Article : Google Scholar : PubMed/NCBI
29	Vandamme M, Pauwels W and Bleecker JD: A case of delayed oxaliplatin-induced pseudo-obstruction: An atypical presentation of oxaliplatin neurotoxicity. Acta Clin Belg. 70:207–210. 2015. View Article : Google Scholar : PubMed/NCBI
30	Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-Momblona X, Iglesias M, Sevillano M, Palomo-Ponce S, Tauriello DV, Byrom D, et al: Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet. 10:320–329. 2015. View Article : Google Scholar
31	Kuroda N, Nakayama H, Miyazaki E, Toi M, Hiroi M and Enzan H: The distribution of CD34-positive stromal cells and myofibroblasts in colorectal carcinoid tumors. Histol Histopathol. 20:27–33. 2005.PubMed/NCBI
32	Sugimoto H, Mundel TM, Kieran MW and Kalluri R: Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther. 5:1640–1646. 2006. View Article : Google Scholar : PubMed/NCBI